Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Mersana Therapeutics, Inc. Director's Dealing 2020

Jan 3, 2020

34702_dirs_2020-01-03_5406bb0d-0687-4afe-a683-59371576d88f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Mersana Therapeutics, Inc. (MRSN)
CIK: 0001442836
Period of Report: 2020-01-02

Reporting Person: Hege Kristen (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-01-02 Stock Option (right to buy) $5.36 A 11264 Acquired 2030-01-02 Common Stock (11264) Direct

Footnotes

F1: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2020.